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Aminoacyl-tRNA synthetases (aaRSs) are a canonical set of enzymes that speciﬁcally attach corresponding amino acids to their
cognate transfer RNAs in the cytoplasm, mitochondria, and nucleus. The aaRSs display great diﬀerences in primary sequence,
subunit size, and quaternary structure. Existence of three types of phenylalanyl-tRNA synthetase (PheRS)—bacterial (αβ)2,
eukaryotic/archaeal cytosolic (αβ)2, and mitochondrial α—is a prominent example of structural diversity within the aaRSs family.
Although archaeal/eukaryotic and bacterial PheRSs share common topology of the core domains and the B3/B4 interface, where
editing activity of heterotetrameric PheRSs is localized, the detailed investigation of the three-dimensional structures from three
kingdoms revealed signiﬁcant variations in the local design of their synthetic and editing sites. Moreover, as might be expected
from structural data eubacterial, Thermus thermophilus and human cytoplasmic PheRSs acquire diﬀerent patterns of tRNA
Phe
anticodon recognition.
1.Introduction
Aminoacyl-tRNA synthetases are primary actors at the ﬁrst
stage of protein translation, catalyzing the attachment of
the correct amino acid to its cognate tRNA in a two-step
reaction [1, 2]. At the ﬁrst step, amino acid is activated by
ATP resulting in formation of an enzyme-bound aminoacyl-
adenylate. In the second step, the amino acid moiety is
transferred onto the 3-terminal ribose of the cognate tRNA,
leading to synthesis of aminoacyl-tRNA. AaRSs vary greatly
in amino acid sequences, three-dimensional structures, and
subunit organizations. After the three-dimensional struc-
tures of four diﬀerent aaRSs from various sources were
determined, analysis of the structures coupled with multiple
sequence alignments led to subdivision of the aaRSs family
into two diﬀerent classes (Table 1)[ 3]. It was shown that
the active site of class I aaRSs is associated with a classical
dinucleotide-binding Rossmann fold, while the active site
of class II is formed by an antiparallel β-sheet ﬂanked by
helices on both sides. Another discrepancy between the
classes is related to the site of amino acid attachment: class
I enzymes attach the amino acid substrate to the 2-OH
group of terminal ribose, whereas class II enzymes attach the
amino acid to the 3-OH group (with PheRS being the only
exception from this rule).
At the amino acid binding and recognition step, some
aaRSs prior to activation face the challenge of discrimination
between amino acids with closely similar chemical struc-
tures. To ensure a high level of total accuracy of protein
biosynthesis, aaRSs developed an additional editing activity
associated with the speciﬁc site where misacylated tRNA
is hydrolyzed [4]. Considerable progress has been made in
revealing the structural basis and mechanisms of noncognate
amino acids discrimination. The proofreading mechanism of
the aaRSs seems to insure discrimination between the correct
substrate and other amino acids. Here we discuss peculiarity
of the aminoacylation reaction in Phenylalanine-speciﬁc
system (Phe-system) and implications of the phenylalanyl-
tRNA synthetase (PheRS) to incorporate noncanonical
amino acids into proteins.2 Journal of Amino Acids
Table 1: Table of division of aaRSs into classes.
Class I aaRSs Class II aaRSs
ValRS, LeuRS, IleRS, CysRS, SerRS, ThrRS, ProRS, GlyRS,
MetRS, ArgRS, GluRS, GlnRS, HisRS, AspRS, AsnRS, PheRS,
TyrRS, TrpRS, LysRS I AlaRS, LysRS II
SepRS, PylRS, hmPheRS
Signature motifs
H I G H ,K M S K S m o t i f1 ,m o t i f2 ,m o t i f3
Architecture of catalytic domains
Rossmann fold Antiparallel fold
Primary site of aminoacylation
2-OH 3-OH (except of PheRS)
2.PheRS:StructuralOrganizationand
Evolution
PheRS is known to be among the most intriguing enzymes
of the aaRSs family. Phylogenetic and structural stud-
ies revealed three major forms of PheRS: (a) (αβ)2-
heterotetrameric eubacterial; (b) (αβ)2-heterotetrameric
archaeal/eukaryotic cytoplasmic; and (c) monomeric mito-
chondrial (Figure 1). The heterotetrameric subunit organi-
zation of prokaryotic and eukaryotic cytoplasmic PheRSs
is markedly conserved in all known species. The bacterial
PheRS from Thermus thermophilus HB8 with 350 residues
per α- and 785 residues per β-subunit is among the well-
documented class II aaRSs [5–9]. Two subunits of the αβ-
heterodimer have no detectable sequence homology. Neither
the α-o rβ-monomers nor the α2-o rβ2-dimers manifest
catalytic activity of tRNA aminoacylation [10]. The α-
subunitofPheRScontainscommontoclassIIaaRSscatalytic
module (CAM, composed of domains A1 and A2), which
together with the N-terminal coiled-coil fragment (CC) is
involved in tRNAPhe binding and aminoacylation (Figure 1).
The β-subunit is a “large” collection of structural domains
including the “catalytic-like” module (CLM, composed of
domains B6 and B7) structurally similar to the CAM, but
catalytically not active, two helix-turn-helix (HTH) “DNA
binding-like” domains, B1 and B5. In addition, the β-
subunit contains an “EMAP II-like” domain (B2) (similar
to the anticodon-binding domain of AspRS and LysRS)
and a “SH3-like” domain (B3/B4), associated with signal
transduction in a number of eukaryotic proteins and with an
editing activity of PheRS [7]. An anticodon binding domain
(B8) with a classical RNA recognition motif that directly
interacts with the anticodon loop of tRNAPhe is located at the
C-terminus of the β-subunit (Figure 1). Thus, the major role
of the β-subunit is in recognition and binding of tRNAPhe.
Structural analysis of the ttPheRS complexed with tRNAPhe
further demonstrated that one tRNAPhe molecule interacts
with all four subunits of the enzyme, thereby explaining why
the enzyme is a functional (αβ)2-heterodimer [8].
A tetrameric organization is not a prerequisite for
aminoacylation activity, as the monomeric mitochondrial
PheRS (hmPheRS) is fully active [11]. HmPheRS, the small-
est known nuclear encoded synthetase, exhibits signiﬁcant
homology tobacterialPheRSs.Infact, hmPheRSis a chimera
of the CAM of the α-subunit and the B8-domain from the β-
subunit of bacterial PheRS (Figure 1). As would be expected,
the 3D structure of mitochondrial enzyme revealed substan-
tialsimilaritytothebacterialrelative,bothinthearchitecture
of individual domains CAM and B8 and in the mode
of substrate recognition [12]. However, when the catalytic
core of the mitochondrial enzyme is superimposed onto
CAM of ttPheRS-tRNAPhe complex, the anticodon binding
domain of hmPheRS interferes with the acceptor stem of
tRNAPhe [12]. Thus, it was hypothesized that formation of
the binary hmPheRS-tRNAPhe complex may be accompanied
by considerable rearrangement of the anticodon-binding
domain; and indeed, very recent biochemical and SAXS
experiments corroborate this hypothesis [13].
Although archaeal/eukaryotic andbacterialPheRSsshare
common architecture of the core domains (two CAMs
from the α-subunits and two CLMs from the β-subunits)
implicated in formation of a four-helix bundle intersub-
unit interface, elongation or shortening at the N- or C-
terminal extremities of the α-a n dβ-subunits have also
been detected in archaeal/eukaryotic PheRSs (Figure 1)
[14, 15]. The extension at the N-terminus of the α-
subunit in archaeal/eukaryotic PheRSs consists of three
structural domains with prototypical DNA-binding folds
(DNA-bindingdomains,DBD)[16,17].Twoofthem(DBD-
1 and DBD-3) belong to a superfamily of “winged helix”
DNA-binding domains (SCOP a.4.5). Furthermore, the
anticodon-binding domain B8 of bacterial PheRSs is missing
from archaeal/eukaryotic enzymes. This results in essential
changes of the architecture of archaeal/eukaryotic enzymes
and in variations of the tRNAPhe binding and recognition
modes as compared to bacterial PheRSs [17].
It is believed that modular design of aaRSs is a result
of a patchwork assembly of diﬀerent functional modules
during the evolution [16]. And PheRS is probably the “tour
de force” collection of diﬀerent RNA- and DNA-binding
modules assembled around the class II catalytic core. The
crucial branch point on the phylogenetic tree of PheRSs
is the subdivision between Bacteria and Archaea lineages.
Although catalytic cores of archaeal/eukaryotic and bacterial
PheRSs display similarity in their heterotetrameric organi-
zation, their anticodon binding domains, to all appearance,
developed independently within the two branches. The
separation into two diﬀerent subclasses of PheRSs is almost
universal and took place at the early stage of separation
between Bacteria and Archaea. From phylogenetic analysis
it follows that hmPheRS is the newest branch evolved from
a bacterial ancestor [18]. In many aspects hmPheRS is
unique among other class II aaRSs. First, it is the smallest
known aaRS, created by massive loss of domains involved
in binding of tRNA and probably of dsRNA/dsDNA, and
in protein quality control. Second, it is the only known
example of monomeric aaRSs containing the class II CAM.
Third, signiﬁcant conformational mobility of the CAM and
of the anticodon-binding domain in hmPheRS is essentialJournal of Amino Acids 3
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Figure 1: Three major forms of PheRS according to phylogenetic and structural studies: (αβ)2-heterotetrameric eubacterial; (αβ)2-
heterotetrameric archaeal/eukaryotic cytoplasmic; monomeric mitochondrial. Schematic representation of α-a n dβ-subunits in terms of
structural domains.
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Figure 2: Crystal structures of ttPheRS and hcPheRS depicted in similar orientations. (a) The crystal structure of ttPheRS in the synthetic
active site area complexed with bound phenylalanyl-adenylate. The principal protein residues forming “edge-to-face” interactions in
aromatic triad are indicated. (b) The crystal structure of hcPheRS in the synthetic active site area. Modeling of complex with phenylalanyl-
adenylate.
factor of the phenylalanylation activity [13]. Interestingly,
the replacement of the heterotetrameric bacterial form of
PheRS by the monomeric one in mitochondria appears to
be universal among eukaryotes.
3.Selection ofthe AminoAcids byPheRSs:
Recognition and Proofreading
A distinctive feature of the bacterial PheRSs active site
topology is the presence of a deep phenylalanine-binding
pocket [6]. The bottom surface of the pocket is parallel
to the phenyl ring of the substrate and is covered by the
invariant glycines, thus providing the space required for
the Phe and ATP molecules. One of the walls and the top
surface of the pocket are covered by hydrophobic residues.
Another wall of the pocket is built up entirely of residues,
which may participate in electrostatic interactions and in
hydrogen bonding. Such anisotropy in the distribution of
hydrophobic and hydrophilic residues within the pocket
unambiguouslyorientstheaminoandcarbonylgroupsofthe
amino acid and of the aminoacyl-adenylate (Phe-AMP) [6].
In bacterial PheRS the speciﬁc recognition of phenylalanine
is achieved by hydrophobic interactions of the substrate
phenyl ring and two neighboring phenyl rings of the protein
(Pheα258 and Pheα260 in ttPheRS) making a “network”
of interactions in which each aromatic pair is arranged in
“edge-to-face” manner (Figure 2(a)). A given anisotropy4 Journal of Amino Acids
HIS-261
GLY-315
GLU-334
Figure 3: TtPheRS editing site with bound Tyr [5]. The protein
residues participating in direct and water-mediated (red spheres)
contacts are shown.
and “network” of interactions between hydrophobic residues
within the phenylalanine-binding pocket is not retained
in archaeal/eukaryotic cytoplasmic PheRSs, since Asnα410
(in human PheRS, hcPheRS) substitutes for Pheα258 (in
ttPheRS) and Tyrα412 which is invariant in all eukaryotic
PheRSs substitutes for ttPheα260 (Figure 2(b)). While the
last substitution may be deﬁned as a conservative change,
then Pheα438 seen in hcPheRSinstead of Valα286 in ttPheRS
is not obvious at all. However, as is seen from the structure of
hcPheRS complexed with phenylalanine, speciﬁc recognition
ofthesmallsubstratestillproceedsviatwoaromaticresidues,
Tyrα412 and Pheα438. Thus, the aromatic triad with “edge-
to-face” type of interactions exists in hcPheRS as well.
However, the recognition elements of hcPheRS are shifted
from the left side of the phenylalanine-binding pocket to
the right one, when compared to ttPheRS (Figures 2(a) and
2(b)).
Among natural amino acids only aromatic amino acids
might be considered as eﬃcient substrates for binding to
PheRS, since the recognition process is essentially driven
by the “network” of aromatic-aromatic interactions. The
kinetic study revealed hydrophobic aromatic L-tryptophan
and slightly polar aromatic L-tyrosine to compete with L-
phenylalanine for the binding to PheRSs, while charged
aromatic L-histidine and hydrophobic aliphatic L-isoleucine
showed no inhibition eﬀect even at 20mM concentration
[5].Tyristheonlynaturalcanonicalaminoacidmisactivated
by PheRSs; the catalytic eﬃciency of the reaction is three
ordersofmagnitudelowerascomparedtothatofthecognate
substrate (primarily due to low aﬃnity). The catalytic site,
in this instance, is suggested to act as a “coarse sieve”,
discriminating noncognate amino acids at the binding
and activation steps by chemical and steric factors. Final
rejection of Tyr is achieved in a separate editing domain
of bacterial and cytoplasmic archaeal/eukaryotic PheRSs by
selective binding and hydrolysis of Tyr-tRNAPhe [5, 19–21]
(as described below). HmPheRSs lacking such activity can
stably attach Tyr to tRNAPhe [22, 23].
HmPheRS largely resembles the bacterial enzyme in
architecture of the amino acid binding pocket [6, 12]. The
noncognate Tyr is bound by human hmP h e R Sw i t ha1 . 7 -
fold higher aﬃnity than by the bacterial PheRS [6, 23]. The
structural basis of this diﬀerence might be associated with
a point mutation when hydrophobic valine in the bacte-
rial enzyme (Valα261 in ttPheRS) is substituted for polar
threonine (Thr235 in hmPheRS). This substitution may
reduce hydrophobic contacts of the Phe-substrate within the
amino acid binding pocket, resulting in its lower aﬃnity to
hmPheRS than to ttPheRS (as evident from the respective
Km values [23]). Appearance of hydroxyl-containing Thr235
at the bottom of the hmPheRS amino acid binding pocket
lends additional credence to the notion of PheRS active site
plasticity.
Editing module of PheRS during evolutionary variations
was speciﬁcally designed for binding and subsequent hydrol-
ysis of Tyr-tRNAPhe. The early fast kinetic study of Lin et al.
demonstrated that tyrosine is indeed transferred to tRNAPhe,
and the misaminoacylated tRNA is very rapidly hydrolyzed
[21]. Recently it was reported that editing activity of the
bacterial and archaeal/eukaryotic PheRSs is associated with
the active site located at the interface region between B3 and
B4 domains in the β-subunit [5, 19, 20]. In ttPheRS the
speciﬁc recognition of the OH group in para position of Tyr
is achieved by its interactions with the Oε1o fG l u β334 and
the main chain amide of Glyβ315 (Figure 3). In accordance
with the structure-based modeling Gluβ334 and Hisβ261
are considered as residues playing critical role in anchoring
Tyr-tRNAPhe within the editing site and its subsequent
hydrolysis. It is of interest that Hisβ261 together with
Gluβ323 coordinates a “catalytic” water molecule which was
observed in several crystal structures of ttPheRS and as such
may be involved in hydrolysis [5] .T h ep r e s e n c eo fH i s β261,
Gluβ334, Asnβ250, Thrβ249, and Gluβ323 in the vicinity of
the ester bond subjected to hydrolysis is reminiscent of the
activesite ofpeptidyl-tRNA hydrolase(PTH)performingthe
hydrolysis of the ester bond between tRNA and the peptide
[24, 25]. Residues Asn10, His20, and Asp93 considered as
being crucial for PTH activity [24, 25] are similar to the
PheRS triad, Asnβ250, Hisβ261, and Gluβ323. These triads
can be superimposed with r.m.s.d. of 1.4 ˚ A for the Cα atoms
in spite the fact that the proteins are not homologues.
Nevertheless the clear structural similarity between two
triads, biochemical experiments suggest that in PTH the
triad seems to be directly involved in catalysis, while the
triad in the editing site of PheRS plays more positional role
ratherthandirectly involved in catalysis.Itis remarkablethat
both the bacterial and archaeal/eukaryotic forms of PheRS
share common editing domain structures, however, PTH
triad is not present in the archaeal enzyme [20]. Hisβ261
appears to be replaced by Gly in archaeal/eukaryotic PheRS.
At ﬁrst glance, this substitution would seem to imply that the
hydrolytic mechanism is diﬀerent in eukaryotic cytoplasmic
(as well as in archaeal) PheRSs. However, detailed inspection
of the editing site shows that in place of the side chain of
Hisβ261 (ttPheRS), a given local area in hcPheRS is occupied
by side chain of Asnβ238 (hcPheRS) or Asn217 (phPheRS),Journal of Amino Acids 5
alsocapableofinteractingwiththephosphoesterbondofthe
Tyr-tRNAPhe.
4. Incorporation of Non-Coding Amino Acids
The aaRSs in general demonstrate a remarkable speciﬁcity
towards their cognate amino acid substrates. As a conse-
quence, binding of odd shaped nonnatural amino acids
in amino acid binding pocket have to be accompanied by
substitution of several residues, respectively, [26]. Notably,
despite the high level of the substrate stereospeciﬁcity,
the active site of PheRS demonstrates a natural plasticity,
enabling binding, activation and speciﬁc aminoacylation of
some Phe surrogates.
Exposure of the phenylalanine to reactive oxygen species
(ROSs) produces multiple isomers of tyrosine—meta-
tyrosine (m-Tyr), ortho-tyrosine (o-Tyr) and standard para-
tyrosine. The ﬁrst two are widely used as an index of
oxidative damage in tissue proteins [27, 28]. Recently it
was shown that hmPheRS catalyzes direct attachment of
naturally occurred derivatives of phenylalanine to tRNAPhe
in eukaryotic cells [23]. Analysis of kinetic parameters of
tRNAPhe aminoacylation shows that the aﬃnity of hmPheRS
to m-Tyr is only ﬁve-fold lower than to the cognate amino
acid phenylalanine. At the same time, the catalytic eﬃciency
of tRNAPhe aminoacylation with physiological Tyr is 1000-
fold lower than that of the phenylalanylation reaction, pri-
marily because of a high Km value [23]. Crystal structure of
hmPheRS complexed with m-Tyr revealed the highly speciﬁc
network of interactions of the molecule. A fragment of
unbiased electron density at the amino acid binding pocket
may be unambiguously attributed to the m-Tyr molecule.
Just as Phe and Tyr, the m-Tyr is involved in aromatic-
aromatic interactions (see above) with two phenylalanines
within the amino acid binding pocket. As compared to
the Phe-substrate, m-Tyr is additionally stabilized by the
hydrogen bonding of its OH-group in meta-position with
the Nε2 atom of Gln124 (2.7 ˚ A), and with the Oε2a t o mo f
Glu159 (2.6 ˚ A).
As compared to bacterial and mitochondrial PheRSs,
hcPheRS binds m-Tyr less eﬃciently (with one order of
magnitude lower aﬃnity) [23]. Modeling experiments indi-
cate that amino acid residues of hcPheRS involved both in
phenylalanine and m-Tyr binding and recognition form a
local environment, which is diﬀerent from those observed in
hmPheRS and ttPheRS (Finarov et al., unpublished results).
The distinguishable features in the amino acids environment
may lead to the observed diﬀerence in the m-Tyr aﬃnity.
The substantial plasticity of the active site and the
structural diversity of PheRSs from diﬀerent kingdoms made
these enzymes of superior tool for introduction of new
amino acids into the protein polypeptide chains. Indeed, the
PheRS enzyme was among the ﬁrst aaRSs used to introduce
Phe analogs into proteins. Ibba et al. [29] have demonstrated
an attachment of the para-halogenated Phe analogs to tRNA
and their in vivo incorporation into cellular proteins by the
E. coli Ala294Gly mutant PheRS (Ala314 in ttPheRS) that
exhibits relaxed substrate speciﬁcity. Further studies revealed
thatphenylalanineanalogssubstitutedwithvariouschemical
groups (bromo-, iodo-, ethynyl-, cyano, and azido-) at
para position were eﬃciently incorporated into recombinant
proteinsbythemutantPheRS[30,31].However,thismutant
failed to suﬃciently incorporate p-acetylphenylalanine into
the proteins. The analysis of PheRSs 3D sructures identiﬁed
another mutation that may be crucial for plasticity and
active site speciﬁcity, the Thr251Gly (Val261 in ttPheRS).
Indeed doubly mutated PheRS (T251G, A294G) as predicted
by the design algorithm eﬃciently incorporates in vivo p-
acetylphenylalanine into recombinant proteins [32]. The net
result of these active-site mutations is formation of the space
inthephenylalaninebindingpocketneededtoaccommodate
sterically demanding para-substituted analogs. Interestingly,
the relaxed speciﬁcity of these mutants appeared to be
directed mainly to the para-position of the amino acid
substrates. However, natural plasticity of the amino acid
binding pocket in ttPheRS allows p-Cl-Phe to be bound and
recognized by the wild-type enzyme [5]. This suggests that
engineered speciﬁcity for one enzyme may be considered as
a natural one for another representative of the family.
It was shown that mutations in the editing module may
be considered as a powerful tool for the incorporation of
novel amino acids. On the other side, mutations within the
editing site may lead to incorporation of non-natural amino
acids into the polypeptide chains and as a consequence to
protein misfolding. This has been demonstrated with AlaRS:
a missence mutation in the editing domain of the alanyl-
tRNA synthetase gene that compromises the proofreading
activity of the enzyme causes cerebellar Purkinje cell loss
and ataxia [33]. Certain PheRSs are able to stably attach
para-substituted Phe analogs to tRNAPhe. Considering the
availability of editing activity in PheRS, appearance of
misacylated tRNAPhe implies that the unnatural amino acid
attached to tRNA is not recognized by the hydrolytic site.
It was proposed that during evolution the editing activity
in PheRS is evolved against Tyr only, yet some recent
observations suggest that editing site also demonstrates
some degree of natural plasticity. The fact that bacterial
PheRS activates m-Tyr, but does not stably attach the
ROS-damaged amino acid to tRNAPhe suggests availability
of the hydrolytic activity. Contrary to bacterial PheRSs,
hcPheRS is unable to hydrolyse m-Tyr-tRNAPhe though it
is fully active against Tyr-tRNAPhe. The low deacylation
activity of hcPheRS against m-Tyr-tRNAPhe suggests that
this substrate is poorly recognized by the editing pocket
of archaeal/eukaryal PheRS. Thus, editing of several diﬀer-
ent substrates by PheRS suggests that plasticity could be
attributed not only to the synthetic active site, but also to the
editing site, capable of binding ligands other than tyrosine.
As it was reported in [34], the editing module of PheRS is
capable to enhance incorporation of tyrosine derivatives into
proteins when attached to tyrosyl-tRNA synthetase (TyrRS).
TyrRSs from various sources have been engineered and used
for the incorporation of unnatural amino acids into proteins
using bacterial and eukaryotic hosts. However, these variants
of TyrRS still produce Tyr-tRNATyr. Thus, the editing
module of archaeal PheRS was transplanted into engineered6 Journal of Amino Acids
3-iodo-tyrosyl-tRNA synthetase (iodo-TyrRS) to edit Tyr-
tRNATyr and thereby to improve the overall speciﬁcity for 3-
iodo-L-tyrosine. The engineered iodo-TyrRS-B3/B4 chimera
exclusively incorporated 3-iodo-ryrosine into the speciﬁed
site of a protein in the wheat germ translation cell-free
system [34]. It is not clear if isolated editing module of
PheRS would have adverse eﬀect on translation in vivo as
it edits not speciﬁcally both Tyr-tRNAPhe and Tyr-tRNATyr.
The most promising attack on this problem appears to
be the engineering of editing domain capable to recognize
speciﬁcally tRNA molecules of interest.
5. Conclusion Remarks
The aaRSs are a notoriously diverse family of enzymes
arose early in evolution, being essential for stepwise evo-
lution of the genetic code. Much evidence suggests that
aromatic amino acids (tyrosine, tryptophan and pheny-
lalanine) were among the last amino acids to be added
to genetic code. Indeed, it seems that both PheRSs and
TyrRSs continue to evolve independent tRNA identity ele-
ments since separation between bacterial and archaeal lin-
eages. Thus, archaeal/eukaryotic TyrRS-tRNATyr and PheRS-
tRNAPhe pairsdonotcross-reactwiththeirbacterialcounter-
parts. Such orthogonality can be used for the incorporation
of unnatural amino acids into proteins upon introduction
of engineered archaeal/eukaryotic PheRSs or TyrRSs into
bacterial cells.
At one time we were under impression that knowledge
of Phe-system was adequate, and future studies of the
enzyme will be referred as an applied research. However,
results highlighting the structural and functional diversity of
PheRSs aﬃrm the various pathways important for biomed-
ical research. The PheRS shows a remarkable speciﬁcity
to their cognate amino acid substrate. As a result, the
incorporation of non-natural amino acids often necessitates
site-directed mutagenesis of the several residues within the
active site area [35]. However, despite the high level of the
substrate stereo-speciﬁcity in the Phe-system, structures of
bacterial and mitochondrial PheRSs demonstrate a natural
plasticity at the active site [5, 23], thus enabling binding and
speciﬁc aminoacylation of surrogates.
Being central components of translation machinery it is
plausible to propose that expression of some aaRSs show
abnormal up- or downregulation in cancer. Indeed, it was
shown that the level of mRNA encoded for alpha-subunit
of the human PheRS is overexpressed in the lung solid
tumors and acute phase chronic myeloid leukemia [36].
An enrichment-based pathway mapping of the androgen-
regulatedproteomicdatasetsrevealedasigniﬁcantdisregula-
tionofaminoacyl-tRNAsynthetasesand,α-subunitofPheRS
inparticular,indicatinganincreaseinproteinbiosynthesis—
a characteristic at some stage of prostate cancer progression
[37]. Recently solved structure of hcPheRS [17]d e m o n -
strated existences of many noncatalytic function domains,
which are involved in a variety of biological functions in
other proteins. Insight into the functional role of these
unique modules and revealing their relationship to the
etiology of cancer, if any, is still to be determined.
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